Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-014401
Filing Date
2025-02-14
Accepted
2025-02-14 21:04:16
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10610
  Complete submission text file 0001104659-25-014401.txt   12410
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Subject) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90054 | Film No.: 25632202
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738
Business Address 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738 512-254-3790
ADAR1 Capital Management, LLC (Filed by) CIK: 0001940272 (see all company filings)

EIN.: 000000000 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13G/A